Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to start review


     Quick Explanation



    This RSC Chemical Biology study (Nov 2024) shows GTP-state KRAS oncogenic mutants G12D/G12C/G12V only mildly shift switch-1 toward the inactive state-1 (wt 30/70 β†’ G12D 50/50, G12V 55/45), while NRAS Q61R fully stabilizes the active state-2 via a transient Arg61–Thr35 hydrogen bond, and MRTX1133 allosterically locks KRAS G12D in state-1, blocking RAF-RBD binding.


     Long Explanation



    Core findings across four orthogonal methods

    The paper integrates Β³ΒΉP NMR, ¹⁡N CPMG relaxation dispersion, HDX-MS, and 10 Γ— 1 Β΅s MD replicates per protein (Amber20, ff19SB) to quantify the state-1/state-2 switch-1 equilibrium in GTP-analog-bound KRAS and NRAS . The headline surprise: codon-12 KRAS oncogenic mutants shift the equilibrium toward the inactive state, opposite to naive expectations of gain-of-function activation.

    Values as reported in the paper's Fig. 2A–C; KRAS G12C plotted at wt levels per authors' statement that it "retains populations similar to wildtype." Exact G12C percentages are not given numerically in the text β€” treated as approximate.

    The Q61R mechanism and the T35S dominance hierarchy

    NRAS Q61R fully shifts to state-2, rationalized by MD as a transient Arg61–Thr35-backbone-carbonyl H-bond (~33% occupancy) consistent with Q61R co-crystal structures (6XGU, 6ZIZ). Strikingly, in the NRAS T35S/Q61R double mutant, T35S dominates β€” losing one methyl group outcompetes the arginine stabilization β€” showing epistasis in the allosteric network .

    MRTX1133 mechanism of action

    Using ΒΉH,ΒΉΒ³C-HMQC competition with RAF1-RBD, the authors show MRTX1133 allosterically prevents effector binding at physiological concentrations: the piperazine–Asp12 salt bridge displaces the Ala59/Gly60 loop, whose Ξ²-methyl pushes Thr35 and flips switch-1 open. RBD quenching only occurs at 100 Β΅M RBD (non-physiological). This is a cleaner, more decisive allosteric MoA than the ambiguous BBO-8956 spectra of Sharma et al. .

    Critical caveats

    • GMPPNP β‰  GTP: the rank order of state-1 population changes slightly between analogs (G12C vs wt swap positions); Β³ΒΉP work is GMPPNP-based, CPMG GTP-based β€” an acknowledged internal inconsistency the authors handle but cannot eliminate.
    • In vitro, dilute, low-temperature (7 Β°C) NMR conditions and MD force-field assumptions (GMPPNP modeled as GTP; Mg²⁺ LJ parameters) mean absolute populations may differ in cells, where membrane anchoring, GEF/GAP, and crowding matter β€” none of which are modeled.
    • HDX-MS coverage gaps at T35S and residue-61 peptides prevent direct switch-1 comparison for key mutants; the authors disclose this.
    • Counterintuitive result demands caution: if G12 mutants slightly favor the inactive state, oncogenicity must reside in nucleotide loading/localization β€” a claim asserted but not tested here (no cellular assays).

    What would falsify the core model: repeat Β³ΒΉP NMR with true GTP and physiological Mg²⁺/temperature showing reversed mutant ordering, or MD with corrected nucleotide parameters failing to reproduce the Arg61–Thr35 H-bond.



    Feedback:    

    Updated: September 30, 2026

     BGPT Paper Review



    Study Novelty

    60%

    The state-1/state-2 paradigm is decades old (Kalbitzer/Hamasaki era) and Sharma et al. 2024 recently published overlapping KRAS 31P NMR mutant data; novelty rests on extending to NRAS Q61R, the Arg61–Thr35 H-bond mechanism, and the MRTX1133 allostery MoA β€” incremental but substantive.



    Scientific Quality

    80%

    Four orthogonal methods converge with quantified populations, uncertainties on CPMG fits, deposited HDX data (PXD054924), and clear disclosure of coverage gaps. Caveats: 7 Β°C NMR conditions, GMPPNP-as-GTP modeling, ~1.3 Γ… RMSD threshold for state classification in MD is heuristic, and no biological/cellular validation. Corporate authorship (Novartis) on inhibitor MoA warrants scrutiny, though declared no conflicts.



    Study Generality

    60%

    Findings center on two RAS isoforms and specific mutants; the state-1/state-2 framework and allosteric-node concept (Ala59, Thr35) generalize to the RAS family, but cellular-context generality is untested.



    Study Usefulness

    80%

    Directly informs G12D/Q61R drug design: conformational state populations offer a screening readout, and the MRTX1133 allosteric relay explains clinical inhibitor function and guides effector-blocking chemotypes.



    Study Reproducibility

    70%

    Detailed expression/purification/NMR/MD protocols; HDX data deposited (PRIDE PXD054924); CPMG WT data reusable from Dryad. MD depends on proprietary MOE preparation; exact 31P state populations rely on spectral deconvolution reproducible only with ESI data.



    Explanatory Depth

    80%

    Mechanistic depth is high: residue-level H-bond occupancies, crystallographic corroboration, epistasis between T35S and Q61R, and a structurally explicit allosteric relay for MRTX1133 β€” though causal links between occupancy percentages and populations remain inferential.


    🎁 Authors: Collect 258 Free Science Tokens (β‰ˆ $25.8 USD)

    Claim My Author Tokens

    Use for 64 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $25.8 USD)

     Top Data Sources ExportMCP



     Analysis Wizard



    Fetching and plotting reported state-1/state-2 31P NMR populations for KRAS/NRAS mutants, and cross-checking CPMG-fitted exchange rates against deposited PRIDE HDX-MS datasets to map mutant-dependent flexibility.



     Hypothesis Graveyard



    'G12D/G12V stabilize the active KRAS conformation' β€” directly contradicted here and by Sharma et al.; codon-12 mutants mildly favor state-1, so oncogenicity must flow through GEF-resistant GTP loading and membrane localization, not switch-1 closure.


    'GTP-bound RAS is uniformly ON, GDP-bound OFF' β€” long falsified by the state-1/state-2 equilibrium (Kalbitzer 2001 onward); this paper extends the two-state picture to NRAS and therapeutic mutants.

     Science Art


    Paper Review: Dynamic conformational equilibria in the active states of KRAS and NRAS Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT